UNIVERSITY OF MIAMI

A study found brolucizumab non-inferior to aflibercept in treating DME, with superior anatomic outcomes. Both drugs showed similar adverse event rates. The meta-analysis underscores the need for further trials to assess safety outcomes for brolucizumab as a DME treatment alternative.

GenomOncology appoints Dr. Jonathan "Jack" Lord, M.D., to its Board of Directors. Dr. Lord, a healthcare innovation leader, brings extensive experience in clinical practice, healthcare administration, and advanced analytics. His appointment aligns with GenomOncology's mission to advance precision medicine in oncology.

Sleep apnea linked to accelerated aging of brain's white matter and increased hippocampus size, potentially harming memory and increasing risk of cognitive decline and dementia.

Jaime Merchan discusses LITESPARK-013 trial results of belzutifan (HIF-2α inhibitor) in advanced clear cell RCC, showing similar efficacy and safety at 120 mg vs 200 mg daily doses. Future research includes belzutifan combinations with TKIs or checkpoint inhibitors, and a phase 3 study in the adjuvant setting with pembrolizumab.

Provectus Biopharmaceuticals launched VisiRose, a clinical-stage biotech focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for eye infections using Provectus’s Rose Bengal Sodium (RBS). RB PDAT, developed with the University of Miami’s Bascom Palmer Eye Institute, treats infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.

Provectus Biopharmaceuticals launched VisiRose, a clinical-stage biotech focused on RB PDAT for eye infections using Rose Bengal Sodium. The University of Miami is a minority shareholder. RB PDAT, based on research from Bascom Palmer Eye Institute, treats infections caused by bacteria, fungi, and parasites.

Provectus Biopharmaceuticals launches VisiRose, a clinical-stage biotech focused on RB PDAT for eye infections, with University of Miami as a minority shareholder.

BostonGene to present research on transcriptomic classification, ADC target analysis, and ctDNA monitoring at 2024 SABCS, aiming to advance precision oncology for breast cancer patients.

Johnson & Johnson seeks approval for Darzalex to treat high-risk smoldering myeloma, with AQUILA trial showing reduced risk of disease progression. GSK's Blenrep, after withdrawal, shows improved survival in DREAMM-7 trial. Emerging efforts aim to ease conditioning for genetic treatments in sickle cell disease. Kura Oncology's menin inhibitor shows promising results in AML, facing competition from J&J and Syndax. Pfizer's Oxbryta withdrawal for sickle cell disease remains unexplained.